Project Grant R21AI181677
Award Date
8/9/24
Completion Date
6/30/26
Dollars Obligated
$229K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The $7,105,240 award, with an ultimate completion date of November 30, 2029, supports a collaborative research program focused on investigating cooperative antibody and T-cell responses,...
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This $3,454,926 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research aimed at developing an HIV-1 vaccine strategy focused on the "apex" epitope of the HIV envelope glycoprotein. The research seeks to identify and characterize HIV broadly neutralizing antibody (bNAb) precursors that target the apex epitope, and to design envelope protein antigens that can...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to design and test novel immunogens for their ability to guide the evolution of the VRC01 B-cell lineage towards a mature phenotype capable of producing broadly neutralizing antibodies against HIV. The total funding amount for this 2-year award is $176,063, with an award date of August 7, 2024 and an...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This $252,280 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to evaluate the role of monocyte cells in the development of an effective HIV vaccine response. The research project aims to investigate changes in monocyte gene expression following HIV infection, autoimmune disease, and vaccination, and to identify monocyte subtypes associated with antibody...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel multi-epitope protease cleavage sites (MEPCS) vaccine for protecting against SIV (Simian Immunodeficiency Virus) rectal transmission. The $650,156 award, effective August 21, 2024 through June 30, 2029, will support comparative evaluations of a cold-chain friendly and long-term stable...